By Josh Beckerman
Shares of Lyell Immunopharma were up 8% after the T-cell reprogramming company said it will collaborate with contract manufacturer Cellares.
The stock was recently at $1.97 and is down about 42% for the year to date.
Lyell and Cellares have agreed on a proof-of-concept technology transfer process for the manufacture of Lyell’s LYL797 CAR T-cell therapy, using the Celares Cell Shuttle platform. LYL797 is in development for the treatment of solid tumors.
Write to Josh Beckerman at [email protected]
Read the full article here
